Publication | Open Access
Treatment with Piperacillin‐Tazobactam and False‐Positive<i>Aspergillus</i>Galactomannan Antigen Test Results for Patients with Hematological Malignancies
184
Citations
11
References
2004
Year
Diagnostic MycologyHematology PatientsImmunologyPathologyHematological MalignanciesLaboratory HematologyHigh RateHematologySerologic TestingLaboratory MedicineHealth SciencesAutoimmune DiseaseAntifungal AgentsMedicineClinical MicrobiologyFungal PathogenAntifungal AgentAntibioticsGm AntigenOncology
We report the occurrence of a high rate of false-positive test results during the surveillance of hematology patients for galactomannan (GM) antigenemia. Among 218 patients surveyed from June 2002 through June 2003, 42 (19.3%) had > or =1 serum sample positive for GM (optical density index, >1.5). Of these patients, 38 had no additional evidence of invasive aspergillosis, and, therefore, their test results were considered to be false-positives. Case-control analysis showed that treatment with piperacillin-tazobactam was the only risk factor significantly associated with receiving false-positive test results. When tested for GM antigen, 3 of 4 piperacillin-tazobactam batches had positive results. Physicians should be aware of the possible interference of treatment with piperacillin-tazobactam when interpreting the results of the GM assay.
| Year | Citations | |
|---|---|---|
Page 1
Page 1